Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.

<h4>Background</h4>Snakebite is a neglected tropical disease that causes high global rates of mortality and morbidity. Although snakebite can cause a variety of pathologies in victims, haemotoxic effects are particularly common and are typically characterised by haemorrhage and/or venom-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nessrin Alomran, Jaffer Alsolaiss, Laura-Oana Albulescu, Edouard Crittenden, Robert A Harrison, Stuart Ainsworth, Nicholas R Casewell
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/7ac00559f88147a1afdb2e22c80d597c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ac00559f88147a1afdb2e22c80d597c
record_format	dspace
spelling	oai:doaj.org-article:7ac00559f88147a1afdb2e22c80d597c2021-12-02T20:23:38ZPathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.1935-27271935-273510.1371/journal.pntd.0009659https://doaj.org/article/7ac00559f88147a1afdb2e22c80d597c2021-08-01T00:00:00Zhttps://doi.org/10.1371/journal.pntd.0009659https://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>Snakebite is a neglected tropical disease that causes high global rates of mortality and morbidity. Although snakebite can cause a variety of pathologies in victims, haemotoxic effects are particularly common and are typically characterised by haemorrhage and/or venom-induced consumption coagulopathy. Antivenoms are the mainstay therapeutic for treating the toxic effects of snakebite, but despite saving thousands of lives annually, these therapies are associated with limited cross-snake species efficacy due to venom variation, which ultimately restricts their therapeutic utility to particular geographical regions.<h4>Methodology/principal findings</h4>In this study we explored the feasibility of generating globally effective pathology-specific antivenoms to counteract the haemotoxic signs of snakebite envenoming. Two different immunogen mixtures, consisting of seven and twelve haemotoxic venoms sourced from geographically diverse and/or medically important snakes, were used to raise ovine polyclonal antibodies, prior to characterisation of their immunological binding characteristics and in vitro neutralisation profiles against each of the venoms. Despite variability of the immunogen mixtures, both experimental antivenoms exhibited broadly comparable in vitro venom binding and neutralisation profiles against the individual venom immunogens in immunological and functional assays. However, in vivo assessments using a murine preclinical model of antivenom efficacy revealed substantial differences in venom neutralisation. The experimental antivenom generated from the seven venom immunogen mixture outperformed the comparator, by providing protective effects against venom lethality caused by seven of the eight geographically diverse venoms tested, including three distinct venoms that were not used as immunogens to generate this antivenom. These findings suggest that a core set of venom immunogens may be sufficient to stimulate antibodies capable of broadly neutralising a geographically diverse array of haemotoxic snake venoms, and that adding additional venom immunogens may impact negatively on the dose efficacy of the resulting antivenom.<h4>Conclusions/significance</h4>Although selection of appropriate immunogens that encapsulate venom toxin diversity without diluting antivenom potency remains challenging and further optimisation is required, the findings from this pilot study suggest that the generation of pathology-specific antivenoms with global utility is likely to feasible, thereby highlighting their promise as future modular treatments for the world's tropical snakebite victims.Nessrin AlomranJaffer AlsolaissLaura-Oana AlbulescuEdouard CrittendenRobert A HarrisonStuart AinsworthNicholas R CasewellPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 15, Iss 8, p e0009659 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Nessrin Alomran Jaffer Alsolaiss Laura-Oana Albulescu Edouard Crittenden Robert A Harrison Stuart Ainsworth Nicholas R Casewell Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
description	<h4>Background</h4>Snakebite is a neglected tropical disease that causes high global rates of mortality and morbidity. Although snakebite can cause a variety of pathologies in victims, haemotoxic effects are particularly common and are typically characterised by haemorrhage and/or venom-induced consumption coagulopathy. Antivenoms are the mainstay therapeutic for treating the toxic effects of snakebite, but despite saving thousands of lives annually, these therapies are associated with limited cross-snake species efficacy due to venom variation, which ultimately restricts their therapeutic utility to particular geographical regions.<h4>Methodology/principal findings</h4>In this study we explored the feasibility of generating globally effective pathology-specific antivenoms to counteract the haemotoxic signs of snakebite envenoming. Two different immunogen mixtures, consisting of seven and twelve haemotoxic venoms sourced from geographically diverse and/or medically important snakes, were used to raise ovine polyclonal antibodies, prior to characterisation of their immunological binding characteristics and in vitro neutralisation profiles against each of the venoms. Despite variability of the immunogen mixtures, both experimental antivenoms exhibited broadly comparable in vitro venom binding and neutralisation profiles against the individual venom immunogens in immunological and functional assays. However, in vivo assessments using a murine preclinical model of antivenom efficacy revealed substantial differences in venom neutralisation. The experimental antivenom generated from the seven venom immunogen mixture outperformed the comparator, by providing protective effects against venom lethality caused by seven of the eight geographically diverse venoms tested, including three distinct venoms that were not used as immunogens to generate this antivenom. These findings suggest that a core set of venom immunogens may be sufficient to stimulate antibodies capable of broadly neutralising a geographically diverse array of haemotoxic snake venoms, and that adding additional venom immunogens may impact negatively on the dose efficacy of the resulting antivenom.<h4>Conclusions/significance</h4>Although selection of appropriate immunogens that encapsulate venom toxin diversity without diluting antivenom potency remains challenging and further optimisation is required, the findings from this pilot study suggest that the generation of pathology-specific antivenoms with global utility is likely to feasible, thereby highlighting their promise as future modular treatments for the world's tropical snakebite victims.
format	article
author	Nessrin Alomran Jaffer Alsolaiss Laura-Oana Albulescu Edouard Crittenden Robert A Harrison Stuart Ainsworth Nicholas R Casewell
author_facet	Nessrin Alomran Jaffer Alsolaiss Laura-Oana Albulescu Edouard Crittenden Robert A Harrison Stuart Ainsworth Nicholas R Casewell
author_sort	Nessrin Alomran
title	Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
title_short	Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
title_full	Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
title_fullStr	Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
title_full_unstemmed	Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
title_sort	pathology-specific experimental antivenoms for haemotoxic snakebite: the impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/7ac00559f88147a1afdb2e22c80d597c
work_keys_str_mv	AT nessrinalomran pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT jafferalsolaiss pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT lauraoanaalbulescu pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT edouardcrittenden pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT robertaharrison pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT stuartainsworth pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms AT nicholasrcasewell pathologyspecificexperimentalantivenomsforhaemotoxicsnakebitetheimpactofimmunogendiversityontheinvitrocrossreactivityandinvivoneutralisationofgeographicallydiversesnakevenoms
_version_	1718374115723706368

Pathology-specific experimental antivenoms for haemotoxic snakebite: The impact of immunogen diversity on the in vitro cross-reactivity and in vivo neutralisation of geographically diverse snake venoms.

Ejemplares similares